Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MYH9
REST API REST API
Homo sapiens
MYH9 is differentially expressed in 274 experiments: 150 organism parts: lung, brain, ... (148 more);, 200 disease states: normal, glioblastoma, ... (198 more);, 89 cell types 373 cell lines 41 compound treatments and 70 other conditions.
Synonyms NMMHCA, NMHC-II-A, MHA, EPSTS, FTNS, DFNA17
Orthologs MYH9 (Gallus gallus)   MYH9 (Bos taurus)   myh9a (Danio rerio)   MYH9 (1 of 2) (Danio rerio)   MYO1 (Saccharomyces cerevisiae)   Myh9 (Mus musculus)   Myh9 (Rattus norvegicus)   zip (Drosophila melanogaster)   myh9 (Xenopus laevis)   MYH9_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term angiogenesis, regulation of cell shape, cytosol, plasma membrane, myosin complex, meiotic spindle organization, integrin complex, actin cytoskeleton reorganization, cell morphogenesis involved in differentiation, protein binding, cleavage furrow, myosin II complex, cell-cell adherens junction, cytoplasm, cell-cell adhesion, cellular component movement, actomyosin contractile ring, cell cortex, protein complex, ruffle, myoblast fusion, ATPase activity, actin filament-based movement, membrane protein ectodomain proteolysis, motor activity, cell leading edge, integrin-mediated signaling pathway, cell adhesion, calmodulin binding, ATP binding, axon guidance, actin cytoskeleton, spindle, neuromuscular junction, meiotic metaphase I, cortical cytoskeleton, nucleus, establishment of meiotic spindle localization, cytokinesis, signalosome, nucleotide binding, actin-dependent ATPase activity, protein homodimerization activity, actin filament binding, protein transport, actin binding, microfilament motor activity, uropod organization, leukocyte migration, immunological synapse, in utero embryonic development, stress fiber, ATP catabolic process, ADP binding, blood vessel endothelial cell migration, platelet formation, uropod, protein anchor, monocyte differentiation, establishment of T cell polarity
InterPro Term Myosin_head_motor_dom, Myosin_N, Myosin_tail, IQ_motif_EF-hand-BS
Gene-Disease Assocation MACROTHROMBOCYTOPENIA AND PROGRESSIVE SENSORINEURAL DEAFNESS, EPSTEIN SYNDROME, SEBASTIAN SYNDROME; SBS, MAY-HEGGLIN ANOMALY; MHA, DEAFNESS, AUTOSOMAL DOMINANT 17; DFNA17, FECHTNER SYNDROME; FTNS
UniProt Accession P35579, Q9UMJ0, Q6ZNL4, Q60FE2, Q5BKV1, B1AH99
Search EB-eye ENSG00000100345
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-MEXP-1251, E-MTAB-24, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (34 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-96, E-GEOD-5258, E-GEOD-24147
K562
3
E-MTAB-37, E-GEOD-96, E-GEOD-24147
MOLT4
2
E-MTAB-62, E-MTAB-37
MCF-7
2
E-GEOD-20081, E-GEOD-3529
SW480
2
E-MEXP-1014, E-GEOD-18005
Daudi
1
E-GEOD-96
367 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-22529, E-GEOD-22373, E-GEOD-3920, E-GEOD-360, ... (44 experiments)

Factor Value U/D Experiments
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
monocyte
2
E-GEOD-22373, E-MEXP-583
not specified
2
E-GEOD-18811, E-GEOD-11755
testis - germ cell
2
E-AFMX-5, E-TABM-145
differentiated
1
E-GEOD-2649
liver cancer
1
E-GEOD-21154
83 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-TABM-15, E-MTAB-62, E-GEOD-5418, ... (59 experiments)

Factor Value U/D Experiments
myxoid liposarcoma
2
E-MTAB-62, E-GEOD-6481
control
2
E-GEOD-8121, E-GEOD-3185
chronic myelogenous leukemia
2
E-MTAB-37, E-GEOD-96
dermatomyositis
2
E-MTAB-62, E-GEOD-1551
neuroblastoma
2
E-MTAB-37, E-MTAB-62
obesity
2
E-MTAB-62, E-GEOD-2508
194 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-GEOD-3720, E-GEOD-5824, ... (23 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-1335, E-MEXP-941
all-trans retinoic acid
1
E-GEOD-995
saline
1
E-GEOD-3026
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
LDL
1
E-GEOD-5741
phenol
1
E-GEOD-6907
35 more value(s).


BioSourceProvider

studied in E-GEOD-19519, E-GEOD-19480

Factor Value U/D Experiments
Coriell Cell Repositories http://ccr.coriell.org/Sections/Search/Search.aspx?PgId=165&q=NA18861
1
1
E-GEOD-19480
Coriell: GM14535
1
E-GEOD-19519
Coriell: GM11994
1
E-GEOD-19519
Coriell: GM11831
1
E-GEOD-19519
Coriell: GM12872
1
E-GEOD-19519
Coriell: GM14382
1
E-GEOD-19519
51 more value(s).


Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2034, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-2466, E-TABM-43, E-GEOD-18005, E-GEOD-1153, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-12773, E-GEOD-21612, E-TABM-127, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-20876, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-426

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-43, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.485 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM